Isomorphic Labs in talks to raise $5bn at a $50bn valuation, Bloomberg reports
THE SO WHAT
A potential $5B raise at a $50B valuation for Isomorphic Labs would mark AI-native drug discovery as a capital-intensive, platform-scale play, not a niche tool. Pharma and biotech operators should assume that access to these AI pipelines becomes a strategic dependency on par with access to manufacturing and clinical networks.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechThe hidden supply chain costs of the AI boom
The AI boom is dragging old-economy constraints—chips, RAM, substrates, logistics—back into boardroom conversations that assumed cloud was infinite. If your roadmap depends on scaling AI workloads, you need a view into upstream component and manufacturing risk, not just GPU pricing on your cloud bill.
Deep & Emerging TechInside the race to build European hardware without China
Europe’s push to build hardware supply chains that route around China is a long-cycle bet on resilience over short-term cost. If you manufacture or depend on specialized components in Europe, start mapping which tiers of your stack are China-exposed and what a premium for on-continent alternatives would do to your unit economics.
Deep & Emerging TechDreamHost admits major cyberattack saw hackers steal customer data and access inboxes
A single software vulnerability at DreamHost exposing login credentials, files, and inboxes is a reminder that your weakest SaaS vendor can become your breach. Inventory which critical data flows through third-party hosting and email providers, and push them for concrete answers on patch cadence, MFA enforcement, and anomaly detection this week.
Deep & Emerging TechKalshi Says It’s Not Like Predatory Sportsbooks. NY’s AG Wants Execs to Prove It.
Regulators are starting to treat prediction markets less like quirky fintech and more like consumer gambling products. If your product blurs the line between trading, betting, and forecasting, assume sportsbook-grade scrutiny on business model, disclosures, and customer outcomes.